- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026 | 353 | GlobeNewswire (Europe) | Today, on 20 August 2026, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
| 12.08. | EQL PHARMA AB: Memprex© (methenamine hippurate) license signed with partner for Hungary | 3 | Cision News | ||
| 07.08. | Earnings Call: EQL Pharma signalisiert schwaches Q1 2026, setzt aber auf spätere Erholung | 2 | Investing.com Deutsch | ||
| 07.08. | Earnings Call: EQL Pharma meldet schwaches erstes Quartal, stellt aber Erholung in Aussicht | 1 | Investing.com Deutsch | ||
| EQL PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.08. | EQL Pharma AB: Interim Report April - June 2026 | 214 | GlobeNewswire (Europe) | EQL is going through a challenging period, with supply disruptions and technically more complex products in the launch phase, which has caused delays
Comments from the CEO
The first quarter of the... ► Artikel lesen | |
| 27.07. | EQL Pharma AB: EQL Pharma recruits Oskar Karmlid as new Chief Supply Chain Officer (CSCO) | 541 | GlobeNewswire (Europe) | EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO). Oskar will join the team in October 2026 and take over from Martin Kristofferson, who currently leads supply chain on interim... ► Artikel lesen | |
| 24.07. | EQL Pharma Annual Report 2025/2026 | 1 | Cision News | ||
| 17.07. | Notice of annual general meeting in EQL Pharma AB | 1 | Cision News | ||
| 15.07. | EQL PHARMA AB: Mellozzan (melatonin) approved in Kazakhstan | 1 | Cision News | ||
| 13.07. | EQL Pharma AB: Memprex© (methenamine hippurate) license signed with partner for Spain | 185 | GlobeNewswire (Europe) | EQL's key product Memprex© has now been licensed for sale in Spain with Gebro Holding GmbH (ltd), a leading local pharmaceutical company specialising in women's health, gynaecology and urology.
There... ► Artikel lesen | |
| 10.07. | Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2026/27 | 2 | Cision News | ||
| 15.06. | EQL Pharma AB: Methenamine hippurate (brand name Cystohipp©) has been launched in Germany | 236 | GlobeNewswire (Europe) | EQL's key product methenamine hippurate has now been launched in Germany by EQL's license partner Dr Pfleger under the EQL-owned brand Cystohipp©.
Cystohipp© is the only methenamine hippurate product... ► Artikel lesen | |
| 08.05. | EQL Pharma AB: Year-end Report April 2025 - March 2026 | 278 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 120.2 million, an increase of 6% from SEK 113.3 million in the previous year. Growth for next year negatively impacted by launch delays, but long-term outlook unchanged.
Comments... ► Artikel lesen | |
| 27.04. | EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO) | 6 | Cision News | ||
| 22.04. | Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26 | 1 | Cision News | ||
| 27.03. | EQL Pharma AB: EQL Pharma CEO sells shares to finance capital gains tax from option redemption | 222 | GlobeNewswire (Europe) | EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025.
Axel Schörling... ► Artikel lesen | |
| 25.03. | EQL Pharma AB: Mellozzan (melatonin) has been approved in Italy | 184 | GlobeNewswire (Europe) | EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026 | 237 | GlobeNewswire (Europe) | Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Resolution on implementation of a long-term incentive program... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Interim Report April - December 2025 | 228 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Comments from the CEO
The third quarter... ► Artikel lesen | |
| 04.12.25 | EQL Pharma AB: EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) | 398 | GlobeNewswire (Europe) | As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 440,85 | -0,85 % | Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis | ||
| UNITED THERAPEUTICS | 430,80 | -0,37 % | UNITED THERAPEUTICS Corp - 8-K, Current Report | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| INDIVIOR PHARMACEUTICALS | 30,000 | +0,67 % | Indivior Pharmaceuticals, Inc. - S-4/A, Registration of securities, business combinations | ||
| CAMURUS | 51,85 | -0,19 % | CAMURUS AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2027 | ||
| BAYER | 48,170 | -1,09 % | Nicht nur Bayer verdient am Weltmarkt mit, ohne überall selbst präsent zu sein: Ein australischer Psychedelika-Anbieter setzt auf dasselbe Grundprinzip | ||
| MERCK KGAA | 131,45 | -0,15 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 140 auf 150 Euro angehoben, aber die Einstufung auf "Equal Weight" belassen. Analyst James Gordon... ► Artikel lesen | |
| YARROW BIOSCIENCE | 27,010 | 0,00 % | Yarrow Bioscience prices $150M public offering of common stock at $26 per share | ||
| BIODEXA PHARMACEUTICALS | 1,295 | -0,38 % | Biodexa Pharmaceuticals PLC: Interim results for the six months ended June 30, 2026 | September 11, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| NOVO NORDISK | 37,045 | -0,15 % | Starke Studiendaten: Neue Hoffnung für Wegovy? Novo Nordisk gelingt überraschender Erfolg | © Foto: Christian Schultz/dpaNovo Nordisk erzielt mit Semaglutid einen starken Studienerfolg bei Kindern. Eine Zahl aus der Phase-III-Studie lässt besonders aufhorchen Enthaltene Werte: DK0062498333Den... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,775 | -0,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| ELI LILLY | 962,10 | +0,06 % | Milliardenwette geplatzt: Pharma-Aktie kassiert schweren Rückschlag | © Foto: Sebastian Gollnow/dpaNovartis enttäuscht mit Pelacarsen und verliert an der Börse deutlich. Jetzt wächst der Druck auf die Pipeline Enthaltene Werte: US0311621009,US5324571083,CH0012005267Den... ► Artikel lesen | |
| DERMAPHARM | 37,400 | -2,35 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| SCHOTT PHARMA | 23,050 | -0,43 % | SCHOTT Pharma: Fair-Value-Signal führt zu 64 % Rendite | ||
| ETON PHARMACEUTICALS | 57,04 | -0,08 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen |
Das Unternehmen EQL PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,74 % bei einem Aktienkurs von 2,265 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EQL PHARMA AB finden Sie auf Wallstreet Online.